BridgeBio Pharma (NASDAQ:BBIO) Price Target Raised to $53.00 at HC Wainwright

BridgeBio Pharma (NASDAQ:BBIO) had its price objective lifted by HC Wainwright from $49.00 to $53.00 in a report released on Tuesday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. HC Wainwright’s price objective suggests a potential upside of 56.57% from the company’s current price. HC Wainwright also issued estimates for BridgeBio Pharma’s Q2 2026 earnings at ($0.77) EPS, Q3 2026 earnings at ($0.73) EPS, Q4 2026 earnings at ($0.65) EPS and FY2026 earnings at ($2.98) EPS.

A number of other analysts have also recently issued reports on BBIO. JPMorgan Chase & Co. raised their target price on shares of BridgeBio Pharma from $44.00 to $50.00 and gave the stock an “overweight” rating in a report on Monday, March 24th. Cantor Fitzgerald restated an “overweight” rating and set a $95.00 price objective on shares of BridgeBio Pharma in a report on Friday, February 21st. Citigroup upped their target price on shares of BridgeBio Pharma from $45.00 to $49.00 and gave the stock a “buy” rating in a research note on Friday, February 21st. Scotiabank lifted their price target on BridgeBio Pharma from $49.00 to $52.00 and gave the company a “sector outperform” rating in a research note on Friday, February 21st. Finally, Redburn Atlantic started coverage on BridgeBio Pharma in a research report on Monday, March 31st. They set a “buy” rating and a $50.00 price objective for the company. One equities research analyst has rated the stock with a hold rating and eleven have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $53.00.

BridgeBio Pharma Stock Down 1.1 %

Shares of NASDAQ BBIO opened at $33.85 on Tuesday. BridgeBio Pharma has a twelve month low of $21.62 and a twelve month high of $39.47. The company’s fifty day moving average is $33.69 and its 200-day moving average is $29.95. The stock has a market cap of $6.44 billion, a price-to-earnings ratio of -11.88 and a beta of 1.08.

BridgeBio Pharma (NASDAQ:BBIO) last posted its earnings results on Thursday, February 20th. The company reported ($1.31) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.09) by ($0.22). The business had revenue of $5.88 million during the quarter, compared to analysts’ expectations of $4.04 million. On average, research analysts anticipate that BridgeBio Pharma will post -3.67 EPS for the current fiscal year.

Insider Transactions at BridgeBio Pharma

In other BridgeBio Pharma news, CFO Brian C. Stephenson sold 4,148 shares of the company’s stock in a transaction on Wednesday, February 19th. The shares were sold at an average price of $36.16, for a total transaction of $149,991.68. Following the sale, the chief financial officer now directly owns 102,464 shares of the company’s stock, valued at approximately $3,705,098.24. This represents a 3.89 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CEO Neil Kumar sold 326,932 shares of the stock in a transaction on Tuesday, January 28th. The shares were sold at an average price of $36.29, for a total transaction of $11,864,362.28. Following the completion of the sale, the chief executive officer now owns 5,371,515 shares of the company’s stock, valued at approximately $194,932,279.35. This represents a 5.74 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 9,694,739 shares of company stock worth $327,308,651 in the last 90 days. Corporate insiders own 24.66% of the company’s stock.

Institutional Trading of BridgeBio Pharma

Several institutional investors and hedge funds have recently bought and sold shares of the business. Ironwood Investment Management LLC increased its holdings in shares of BridgeBio Pharma by 0.5% during the 4th quarter. Ironwood Investment Management LLC now owns 63,157 shares of the company’s stock worth $1,733,000 after acquiring an additional 338 shares during the last quarter. GAMMA Investing LLC raised its position in shares of BridgeBio Pharma by 71.0% in the first quarter. GAMMA Investing LLC now owns 920 shares of the company’s stock valued at $32,000 after purchasing an additional 382 shares during the period. Summit Investment Advisors Inc. lifted its stake in shares of BridgeBio Pharma by 3.3% during the 4th quarter. Summit Investment Advisors Inc. now owns 14,706 shares of the company’s stock worth $404,000 after buying an additional 466 shares during the last quarter. Steward Partners Investment Advisory LLC boosted its holdings in shares of BridgeBio Pharma by 85.8% during the 4th quarter. Steward Partners Investment Advisory LLC now owns 1,022 shares of the company’s stock worth $28,000 after buying an additional 472 shares during the period. Finally, Mackenzie Financial Corp increased its stake in shares of BridgeBio Pharma by 6.6% during the fourth quarter. Mackenzie Financial Corp now owns 9,505 shares of the company’s stock worth $261,000 after purchasing an additional 592 shares during the period. Institutional investors own 99.85% of the company’s stock.

About BridgeBio Pharma

BridgeBio Pharma, Inc, a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD.